We believe signatures are the universal language of systems.
Sarborg Limited is an agentic AI signature intelligence business. We build autonomous agents that identify, interpret, and generate high-value opportunities across multiple sectors - from human therapeutics to agricultural chemistry.
Our core thesis is simple: every biological, chemical, and industrial system emits a signature. By encoding those signatures into a common language, we make them comparable, learnable, and exploitable by an agentic network that compounds its intelligence with every match.
The result is a continuously evolving discovery engine - one that can move a question from raw input to ranked, mechanistically-explained output in less time than it takes to read a paper.
One agentic platform. Three pillars of value.
Signature Agent
Our autonomous agent encodes, matches, and ranks signatures across drugs, diseases, and chemicals - delivering ranked indications in under five minutes.
See the agent →Signature Libraries
Six proprietary databases - over 15,000 curated signatures across human disease, rare disease, agrichemicals, veterinary, and bacterial systems.
Explore the databases →Asset Portfolio
Owned technology patents and a growing pharmaceutical portfolio of solid-form and cocrystal assets identified through the signature network.
See the portfolio →Why companies partner with Sarborg.
Unlock underrealised value
We surface hidden potential in existing assets - turning overlooked molecules, formulations, and datasets into actionable, high-value opportunities.
Repurposing opportunities
Our signature network identifies novel indications and new therapeutic contexts for assets that may have stalled or been shelved.
Combination opportunities
We map synergistic pairings across portfolios - revealing fixed-dose combinations, adjuvant strategies, and multi-target approaches that solo analysis misses.
Exclusive portfolio insights
Partners gain privileged access to our proprietary signature libraries and agentic analysis, illuminating whitespace and competitive positioning in their asset landscape.
Intelligent capital allocation
By ranking opportunities by mechanistic fit, market whitespace, and technical feasibility, we help ensure R&D and M&A capital is deployed where it delivers the highest return.
Speed to decision
What traditionally takes months of manual review, our agents deliver in under five minutes - compressing due diligence and accelerating deal timelines.
The signatures behind every match.
Patents across technology and pharma.
- Signature Agent63/981,801
- PRISM Agrichemical Agent64/022,276
- THCA17/999,315
- CBDA12,319,649
- CBG17/640,822
- CBDA Choline63/919,886
- Cystic Fibrosis Asset 164/058,811
- Cystic Fibrosis Asset 264/058,811